| 生物活性 |
Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM that blocks the ATP-binding sites of Cdk2/A and Cdk9/T1, inhibits the PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling pathways, and upregulates hepatic LXRα expression, while also inducing S-phase cell cycle arrest, ROS generation, and apoptosis (apoptosis), and exhibiting anti-inflammatory activity, making it applicable to research on leukemia, pancreatic cancer, prostate cancer, breast cancer, central nervous system cancers, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis. |
| IC50 & Target |
|
|
|
CDK2/A
7.5 μM (IC50)
|
CDK9/T1
0.3 μM (IC50)
|
|
体外研究 (In Vitro) |
Rohitukine (48 h) 表现出选择性的体外癌细胞细胞毒性,对 HL-60 白血病细胞的活性最强 (GI50 = 10 μM),对 Molt-4 白血病细胞的活性次之 (GI50 = 12 μM),而对正常 fR2 和 HEK-293 细胞系的细胞毒性极低 (GI50 > 50 μM)。 Rohitukine (1-10 μM) 可在体外以浓度依赖的方式诱导 HL-60 白血病细胞发生 S 期细胞周期阻滞。 Rohitukine 可在无细胞生化实验中强效抑制 Cdk9/cyclin T1 (IC50 = 0.3 μM),并弱效抑制 Cdk2/A (IC50 = 7.3 μM)。 Rohitukine (50 μM) 在无细胞谱分析实验中可强效抑制 Dyrk1A、AMPK 和 VEGFR 激酶。 Rohitukine (5-20 μM; 2-8 days) 可呈浓度和时间依赖性抑制 3T3-L1 和 C3H10T1/2 脂肪细胞中的脂质积累。 Rohitukine (20 μM; 6 days) 可下调 3T3-L1 脂肪细胞中促脂肪生成基因 (LPL、aP2、SREBP-1c、FAS、PPARγ) 的表达,并上调抗脂肪生成基因 (Wnt3a、GATA2) 的表达。 Rohitukine (20 μM; 15 min-6 days) 可下调晚期成脂蛋白的表达 (PPARγ、C/EBPα、aP2、FAS、GLUT4),抑制 3T3-L1 脂肪细胞中的早期 AKT/mTOR/4EBP 信号通路。 Rohitukine (1-20 μM; 24 h) 可呈浓度依赖性地将 3T3-L1 前脂肪细胞阻滞于有丝分裂克隆扩增过程的 S 期。 Rohitukine (20 μM; 16-24 h) 可下调 3T3-L1 前脂肪细胞中细胞周期进程相关蛋白 (cyclin-D、CDK6、CDK4、cyclin-E、CDK2、C/EBPβ) 的表达,并稳定 CDK 抑制剂 P27。 Rohitukine (20 μM; 48 h) 可显著抑制有丝分裂克隆扩增阶段 3T3-L1 前脂肪细胞的增殖。 Rohitukine (3-100 μM; 24 h) 对 J774A.1 巨噬细胞无细胞毒性,其细胞毒性 IC50 >50 μM。 Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可剂量依赖性地抑制 LPS (MS-X54539) 诱导的 J774A.1 巨噬细胞中一氧化氮的产生。 Rohitukine (3-30 μM; 18 h) 抑制 LPS 诱导的 J774A.1 巨噬细胞中活性氧的生成。 Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可抑制 LPS 诱导的 J774A.1 巨噬细胞中 IL-1β、TNF-α、IL-6 和 PGE2 的产生。 Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) 可剂量依赖性地抑制 LPS 诱导的 J774A.1 巨噬细胞中 NF-κB 的转录活性。 Rohitukine (10-30 μM; 1 h pretreatment, followed by incubation) 可在 10 μM 和 30 μM 浓度下抑制 LPS 诱导的 J774A.1 巨噬细胞中 NF-κB 的核转位。 Rohitukine (10-30 μM; 1 h pretreatment, followed by 2 h incubation) 可抑制 LPS 诱导的 J774A.1 巨噬细胞中 iNOS 和 COX-2 蛋白表达。 Rohitukine (10-30 μM; 1 h pretreatment, followed by 30 min incubation) 可通过降低 IκB-α 磷酸化水平并维持胞质 NF-κB p65 的含量,抑制 LPS 诱导的 NF-κB 通路激活;还可通过降低 ERK 和 JNK 的磷酸化水平,抑制 LPS 诱导的 MAPK 通路激活。 Rohitukine (3-30 μM; 48 h) 对原代小鼠腹腔巨噬细胞的毒性极低,在浓度高达 50 μM 时仍无毒性,并可剂量依赖性地抑制 LPS 诱导的 NO 生成以及 IL-1β、IL-6 和 TNF-α 的释放。 Rohitukine (0.25-1.0 mM) 可剂量依赖性地抑制 5 周龄野生型拟南芥 (Col-0) 植株的生长。 Rohitukine (0.25-1.0 mM) 可呈剂量依赖性诱导 5 周龄野生型拟南芥 (Col-0) 植株中 ROS 的积累,并提高其抗氧化酶活性。
Cell Differentiation Assay
| Cell Line: |
3T3-L1, C3H10T1/2 adipocytes |
| Concentration: |
5; 10; 15; 20 μM |
| Incubation Time: |
2; 4; 6; 8 days |
| Result: |
Inhibited lipid accumulation in a concentration-dependent manner. Significantly reduced lipid accumulation at 5 μM. Inhibited >80% of MDI-induced lipid accumulation at 20 μM in both cell lines. Reduced lipid accumulation across all time windows of 20 μM exposure, with maximum inhibition seen with 0-6 days exposure. Caused a significant reduction in lipid accumulation in 3T3-L1 cells with the shortest 0-2 days exposure. |
Real Time qPCR
| Cell Line: |
3T3-L1 adipocytes |
| Concentration: |
20 μM |
| Incubation Time: |
6 days (gene expression); 48 h (Wnt3a/GATA2 expression) |
| Result: |
Significantly reduced mRNA expression of pro-adipogenic genes LPL, aP2, SREBP-1c, FAS, and PPARγ. Caused a nonsignificant decreasing trend in C/EBPα mRNA expression. Increased mRNA expression of anti-adipogenic transcription factors Wnt3a and GATA2 significantly after 48 h of exposure. |
Western Blot Analysis
| Cell Line: |
3T3-L1 adipocytes |
| Concentration: |
20 μM |
| Incubation Time: |
15; 30; 60; 120 min; 2; 4; 6; days |
| Result: |
Significantly suppressed late-phase protein expression of PPARγ, C/EBPα, aP2, FAS, and GLUT4 on days 2, 4, and 6 of differentiation. Significantly reduced phosphorylation of AKT (Ser473), mTOR (Ser2448), and 4EBP (Thr37/46) within 2 hours of induction. |
Cell Cycle Analysis
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
1; 3; 10; 20 μM |
| Incubation Time: |
24 hours |
| Result: |
Caused a concentration-dependent increase in the percentage of cells in S phase. Induced S-phase arrest during mitotic clonal expansion, with 41.15% of cells in S phase at 20 μM, compared to 19.28% in MDI-only treated cells. |
Western Blot Analysis
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
20 μM |
| Incubation Time: |
16; 24 h |
| Result: |
Reduced protein expression of cyclin-D, CDK6, CDK4, cyclin-E, CDK2, and C/EBPβ at 16 and 24 hours post-induction. Stabilized expression of the CDK inhibitor P27. |
Cell Viability Assay
| Cell Line: |
J774A.1 macrophage cells |
| Concentration: |
3; 10; 30; 100 μM |
| Incubation Time: |
24 h |
| Result: |
Showed no cytotoxic effects across all tested concentrations, with cell viability remaining near control levels both with and without LPS co-treatment. Determined a cytotoxic IC50 >50 μM. |
ELISA Assay
| Cell Line: |
J774A.1 macrophage cells |
| Concentration: |
3; 10; 30 μM |
| Incubation Time: |
1 h pretreatment, followed by 18 h incubation |
| Result: |
Inhibited LPS-induced release of IL-1β (46%), TNF-α (29%), IL-6 (31%), and PGE2 (48%) at 30 μM compared to the LPS-only control. Showed inhibitory effects at lower concentrations in a dose-dependent manner. |
Immunofluorescence
| Cell Line: |
J774A.1 macrophage cells |
| Concentration: |
10; 30 μM |
| Incubation Time: |
1 h pretreatment |
| Result: |
Significantly reduced LPS-induced nuclear translocation of NF-κB, as measured by decreased fluorescent intensity of nuclear NF-κB. Showed statistically significant inhibition at both 10 μM and 30 μM compared to the LPS-only group. |
Western Blot Analysis
| Cell Line: |
J774A.1 macrophage cells |
| Concentration: |
10; 30 μM |
| Incubation Time: |
1 h pretreatment, followed by 2 h incubation |
| Result: |
Reduced LPS-induced iNOS and COX-2 protein levels by 54% and 68%, respectively, at 30 μM. Produced significant inhibitory effects on both proteins at 10 μM. |
Western Blot Analysis
| Cell Line: |
J774A.1 macrophage cells |
| Concentration: |
10; 30 μM |
| Incubation Time: |
1 h pretreatment, followed by 30 min incubation |
| Result: |
Downregulated LPS-induced phosphorylation of IκB-α. Reduced LPS-induced depletion of cytosolic NF-κB p65. Inhibited LPS-induced phosphorylation of ERK (27% inhibition at 30 μM) and JNK (54% inhibition at 30 μM). |
|
体内研究 (In Vivo) |
Rohitukine (50 mg/kg;口服;每日 1 次;连续 7 天) 可显著改善叙利亚金黄仓鼠由高脂饮食诱导的血脂异常,减少肝脏和性腺的脂质积累,并调控关键的脂类调节基因与蛋白。 Rohitukine (12.5-50 mg/kg;口服;每日一次;连续 5 天) 可剂量依赖性地抑制 LPS 诱导的小鼠促炎细胞因子产生。 Rohitukine (12.5-50 mg/kg;口服;单次给药) 可剂量依赖性地降低小鼠体内醋酸 (MS-H89626) 诱导的血管通透性。 Rohitukine (12.5-50 mg/kg;口服;单剂量) 可剂量依赖性地抑制角叉菜胶 (MS-L60716) 诱导的大鼠足肿胀。 Rohitukine (12.5-50 mg/kg;口服;单次给药) 可抑制角叉菜胶诱导的小鼠胸膜炎。 Rohitukine (12.5-50 mg/kg;口服;每日一次;连续 14 天) 可剂量依赖性地减轻 Wistar 大鼠中弗氏完全佐剂诱导的关节炎。
| Animal Model: |
Syrian golden hamster (8-week-old, 100-120 g body weight, dyslipidemia induced by 45% kcal high-fat diet for 10 days) |
| Dosage: |
50 mg/kg |
| Administration: |
p.o.; once daily; 7 days |
| Result: |
Reduced body weight gain significantly compared to HFD and pair-fed groups. Reduced plasma total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol levels significantly relative to the pair-fed group. Increased HDL-cholesterol/total cholesterol ratio significantly. Increased hepatic mRNA expression of liver X receptor α 4-fold. Reduced LDL receptor, HMG-CoA reductase, and sterol-regulatory element binding protein 2 expression significantly. Decreased epididymal adipose tissue weight significantly compared to HFD-fed animals. Reduced protein expression of peroxisome proliferator-activated receptor γ, fatty acid synthase, adipocyte protein 2, and glucose transporter 4 in epididymal adipose tissue. Reduced lipid accumulation in liver, smaller adipocyte size, and reduced pancreatic lipid droplets compared to HFD-fed hamsters. |
| Animal Model: |
BALB/c mice (male, 22-25 g, LPS-induced pro-inflammatory cytokine production model) |
| Dosage: |
12.5; 25; 50 mg/kg |
| Administration: |
p.o.; daily; 5 days |
| Result: |
Inhibited LPS-induced IL-1β production by 58%, TNF-α production by 45%, and IL-6 production by 38% at 50 mg/kg. Significantly reduced IL-1β and TNF-α levels at 25 mg/kg. Reduced IL-1β, TNF-α, and IL-6 levels compared to the LPS-only group at 12.5 mg/kg. |
| Animal Model: |
BALB/c mice (male, 22-25 g, acetic acid-induced vascular permeability model) |
| Dosage: |
12.5; 25; 50 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Reduced Evans blue leakage by 12.1% at 12.5 mg/kg, 39.3% at 25 mg/kg, and 75.7% at 50 mg/kg compared to the acetic acid control group. |
| Animal Model: |
Wistar rats (male, 120-140 g, Carrageenan (MS-L60716)-induced paw oedema model) |
| Dosage: |
12.5; 25; 50 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Suppressed paw oedema by 25% at 12.5 mg/kg, 35% at 25 mg/kg, and 58% at 50 mg/kg compared to the carrageenan control group. |
| Animal Model: |
BALB/c mice (male, 22-25 g, carrageenan-induced pleurisy model) |
| Dosage: |
12.5; 25; 50 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Inhibited pleuritic exudate volume by 59.95% and total leukocyte migration by 86.04% at 50 mg/kg. Inhibited exudate volume by 61.43% and leukocyte migration by 82.43% at 25 mg/kg. Inhibited exudate volume by 5.90% and leukocyte migration by 36.82% at 12.5 mg/kg. |
| Animal Model: |
Wistar rats (male, 120-140 g, Freund's complete adjuvant-induced arthritis model) |
| Dosage: |
12.5; 25; 50 mg/kg |
| Administration: |
p.o.; daily; 14 days |
| Result: |
Inhibited paw oedema by 54%, reduced TNF-α levels by 52%, IL-6 levels by 68%, and IL-1β levels by 71% compared to the arthritic disease control group at 50 mg/kg. Restored serum SGPT, creatinine, and triglyceride levels to near normal at 50 mg/kg. Augmented serum SOD, CAT, and GST levels by 96%, 94%, and 98% respectively compared to the arthritic group at 50 mg/kg. Improved spontaneous motor activity to 39.90 at 50 mg/kg. Maintained joint architecture with reduced bone erosion on radiographs at 50 mg/kg. Prevented body weight loss in all treated groups. |
|